Home | Business News | Browse by Publication | P | Pharmaceutical Technology Europe

Counterfeits: reducing the growing threat: steps companies can take to help safeguard patients and the pharma supply chain.

Publication: Pharmaceutical Technology Europe
Publication Date: 01-APR-09
Format: Online
Delivery: Immediate Online Access

Article Excerpt
The value of counterfeit drugs sold globally is estimated at more than $35 billion (ebsolon 27.5 billion) and the US Center for Medicines in the Public Interest recently predicted that this figure could reach $75 billion (ebsolon 58.9 billion) by 2010. A report by the International Medicinal Products Anti-Counterfeiting Taskforce (IMPACT)--created by the World Health Organization (WHO) in 2006 to mobilize awareness and action in the fight against counterfeit drugs--stated that 10-30% of medicines for sale in much of the developing world are counterfeit. For medicines purchased via the internet from sites that conceal their physical location, IMPACT estimates that up to 50% may be counterfeit. (1)

Counterfeit medicines can range from 'copycat' medicines that contain the declared active ingredient, to those with inactive preparations or random mixtures of toxic substances. All counterfeits are dangerous because their content and quality are unknown. WHO has documented thousands of cases worldwide of counterfeit medicines causing serious illnesses or death because of substandard, ineffective or toxic ingredients. The threat is particularly acute in developing countries where counterfeit treatments for life-threatening conditions such as malaria and HIV are commonly available.

In addition to their impact on global public health, counterfeit drugs pose a serious threat to the pharmaceutical industry--both to the sales of specific products and to the reputation of the industry as a whole. With the tremendous costs and challenges of bringing new therapies to market, pharmaceutical companies cannot afford the additional threat of having a product's efficacy or safety called into question because of ineffective or dangerous counterfeits. There has been much progress within the industry to test sophisticated technologies such as radio-frequency identification (RFID) to combat counterfeiting, but widespread implementation of any technological solution is still some time away. However, there are numerous steps a company can take immediately to help prevent...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharmaceutical Technology Europe
When the going gets tough ... pharmaceutical technology Europe (PTE) t..., April 01, 2009
Upcoming technologies to facilitate more efficient biologics manufactu..., April 01, 2009
Achema 2009: Frankfurt readies itself for international congress ..., April 01, 2009
Drug discovery the cheap way., April 01, 2009
Managing the risks of PAT: operational excellence awaits, but only if ..., April 01, 2009

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.